Disc Medicine Bitopertin APOLLO Results Lift Approval Odds
Disc Medicine bitopertin posted APOLLO success and lifts approval odds, likely prompting traders to reprice risk and increase share and options demand.
KEY TAKEAWAYS
- APOLLO met co-primary and all secondary endpoints; whole-blood PPIX fell 41.4% versus placebo.
- Month-six pain-free light exposure increased 12.2 hours versus placebo, showing meaningful symptom benefit.
- Company plans NDA resubmission by Dec. 31, 2026, and anticipates an FDA decision by mid-2027.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Disc Medicine reported on Oct. 19, 2026, that its pivotal Phase 3 APOLLO trial of bitopertin met both co-primary and all secondary endpoints, showing significant biomarker and symptom improvements. The company plans to resubmit a New Drug Application (NDA) by Dec. 31, 2026, aiming for an FDA decision by mid-2027.
APOLLO Trial Results and Safety
The APOLLO trial was a randomized, double-blind, placebo-controlled Phase 3 study evaluating oral bitopertin in 183 adults and adolescents aged 12 or older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria. Patients across the United States, Canada, Europe, and Australia were randomized 1:1 to receive 60 milligrams of bitopertin once daily or placebo for six months.
The trial showed a 41.4% reduction in whole-blood metal-free protoporphyrin IX (PPIX) from baseline compared with placebo (p<0.0001). Patients treated with bitopertin experienced an average increase of 12.2 hours in monthly pain-free light exposure during month six versus placebo (p=0.0010). Secondary endpoints demonstrated significant reductions in phototoxic reaction rates and increased cumulative pain-free light exposure (both p<0.0001). Among adults, average daily sunlight exposure to prodrome improved (p=0.0077). Patient-reported outcomes, including the Patient Global Impression of Change and Severity, also showed significant improvement versus placebo (each p<0.0001).
Bitopertin was generally well tolerated. Dizziness was the most common treatment-emergent adverse event, affecting 50% of patients, but these events were mild or moderate and typically transient. No treatment-emergent adverse events above Grade 3 were reported, and no new safety signals emerged.
Regulatory Path and Timing
Disc Medicine plans to resubmit its NDA to the U.S. Food and Drug Administration by the end of 2026. The company expects an FDA decision by mid-2027, though no formal FDA action date, review designation, or acceptance of the resubmission has been disclosed. The company filed a Form 8-K with the SEC at 7:08:08 a.m. ET on Oct. 19, 2026, including the press release as Exhibit 99.1.
Bitopertin remains investigational and is not approved for use in any jurisdiction worldwide. The APOLLO topline results and the company’s regulatory timetable provide a defined approval window that investors can incorporate into 2027 forecasts.
"The trial met all its primary and secondary endpoints," the company said in its Oct. 19 press release.
